Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Businessman on Red and white sailing boat in the ocean, Leadership and Business concept, Creative idea, Future success. Paper art vector and illustration. The sky after Raining and big strom.

Earnings

Pfizer is a 2029 story but Q126 lays foundation for growth

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

May 5, 2026

3 min read

Annalee Armstrong

Factory closed with disappointed worker doodle cartoon illustration. Industrial shutdown. Layoff in manufacturing plant closure 2D flat character isolated on white. Doodleart hand-drawn drawing

Layoffs

BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

May 5, 2026

2 min read

Nick Paul Taylor

Abstract blue and purple DNA molecule helix and brain. Genetic biotechnology engineering concept. Low poly style design. Geometric background. Wireframe light graphic connection structure. Vector

ALS

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. On Tuesday, QurAlis presented interim Phase 2 data showing the potential of a similar drug to more broadly treat the neurodegenerative disease.

May 5, 2026

4 min read

Heather McKenzie

Red and blue neon stairs going up to a cloud with dark background and reflections. 3d render

Earnings

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.

May 5, 2026

2 min read

Annalee Armstrong

A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.

MASH

Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.

May 5, 2026

2 min read

Tristan Manalac

Earnings

Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

May 5, 2026

2 min read

Tristan Manalac

Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.

Obesity

Foundayo’s liver failure blip weighs down Lilly shares but analysts unconcerned

The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.

May 5, 2026

2 min read

Tristan Manalac

Exclusive magazine sketch collage image of happy businesswoman businessman stand question mark strategy ceo magnifier search job.

Government

FDA uncertainty persists as search for Prasad successor at CBER drags on

The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming month or two. For now, the appointment of acting director Katherine Szarama has not allayed the industry’s concerns.

May 5, 2026

2 min read

Tristan Manalac